Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT03357107 Completed - Clinical trials for Supraglottic Squamous Cell Carcinoma

Local Control After Robot-assisted Supraglottic Laryngectomy

Start date: October 1, 2016
Phase: N/A
Study type: Observational

Transoral robotic surgery is an option to treat supraglottic squamous cell carcinomas. Oncological outcomes 2 years after transoral robotic surgery for supraglottic laryngectomy were studied.

NCT ID: NCT03356587 Recruiting - Clinical trials for Head and Neck Neoplasms

A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy

Start date: October 16, 2017
Phase: Phase 2
Study type: Interventional

Open, multicenter, single arm, phase II, biomarker driven umbrella trial for head and neck squamous cell carcinoma (FGFR inhibitor, CDK4/6 inhibitor, pan HER inhibitor, PI3K inhibitor, PD1/PD-L1 inhibitor)

NCT ID: NCT03353077 Completed - Clinical trials for Skin Squamous Cell Carcinoma

Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)

Start date: November 21, 2017
Phase: N/A
Study type: Interventional

A unique approach for Skin Squamous Cell Carcinoma (SCC) treatment employing intratumoral diffusing alpha radiation emitter device

NCT ID: NCT03349710 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Start date: December 15, 2017
Phase: Phase 3
Study type: Interventional

This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin

NCT ID: NCT03345966 Not yet recruiting - Clinical trials for Oral Squamous Cell Carcinoma

Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

The aim of the current study is to assess the validation of Bmi-1 detection at both protein and molecular levels in oral epithelial dysplasia and oral squamous cell carcinoma as a biomarker for early cancer detection versus biopsy embedded in paraffin blocks.

NCT ID: NCT03342911 Completed - Clinical trials for Stage IVA Oropharyngeal Squamous Cell Carcinoma

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Start date: November 13, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab, carboplatin, and paclitaxel work in treating patients with stage III-IV head and neck squamous cell carcinoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab, carboplatin, and paclitaxel may work better in treating patients with head and neck squamous cell carcinoma.

NCT ID: NCT03342352 Withdrawn - Clinical trials for Head and Neck Cancer

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Start date: December 15, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the combination of nivolumab plus epacadostat in combination with chemotherapy in first-line recurrent or metastatic patients with squamous cell carcinoma of the head and neck (SCCHN) when compared to the standard of care (EXTREME regimen).

NCT ID: NCT03341936 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck. The immunotherapy drugs involved in this study are: - Nivolumab (Opdivoâ„¢) - Lirilumab

NCT ID: NCT03336606 Active, not recruiting - Clinical trials for Head and Neck Cancer

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Start date: July 25, 2018
Phase: Phase 1
Study type: Interventional

This clinical trial will evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for patients with head and neck squamous cell carcinoma or melanoma.

NCT ID: NCT03333694 Terminated - Clinical trials for Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Start date: December 15, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this first in human and proof of concept study is to characterize the safety, tolerability and initial efficacy of CLL442 in patients with Squamous Cell Carcinoma in situ (SCCis) to enable further clinical development of CLL442.